Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets

Fig. 3

Anti-proliferative effects of receptor tyrosine kinase inhibitors against liposarcoma cells. a Heat map of IC50 values of receptor tyrosine kinase inhibitors arranged according to their cytotoxic efficacy (results derived from Fig. 1). Color bars indicate most sensitive (dark red) to most resistant (dark blue) cell lines. b The table shows top three most potent inhibitors (ponatinib, dasatinib, and sunitinib) and their known primary targets indicating KIT as a common target (highlighted in red). c Individual dose-response curves (MTT assay) of liposarcoma cell lines to dasatinib and ponatinib at different concentrations for 3 days. Experiments were done in triplicates, repeated 3 times and represent the mean ± SE. d IC50 values were calculated from graphs shown in c

Back to article page